Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting

Precipio Inc. (NASDAQ: PRPO) is urging shareholders to vote immediately to reach the 50% quorum requirement for its Annual Shareholders Meeting scheduled for June 15, 2026. As of the press release date, only 42% of shares had been voted. The company is seeking to avoid costly adjournment and rescheduling expenses if sufficient votes are not received by the June 14 deadline.

06/12/2026, 1:00 PM • GlobeNewswire

Precipio to Present at the Planet MicroCap Las Vegas

Precipio, Inc. (NASDAQ: PRPO), a specialty cancer diagnostics company, announced it will present at the Planet MicroCap Las Vegas 2026 conference on June 17, 2026. CEO Ilan Danieli and COO Zaki Sabet will host the presentation. The company emphasized it is profitable and focused on raising awareness and building its shareholder base rather than raising capital.

06/11/2026, 5:00 PM • GlobeNewswire

Precipio Announces Q1 2026 Financial Results

Precipio, Inc. (NASDAQ: PRPO) reported Q1-2026 revenue of $6.71M, essentially flat compared to Q4-2025, driven by timing dynamics including delayed product shipments and CMS cuts. Adjusted EBITDA declined to $(0.16)M from $0.96M in Q4-2025, impacted by lower gross profits, new hiring costs, and bonus payments. Management attributes the flat performance to temporary factors and expects second-half growth from an expanding product pipeline developed by the newly hired commercial team.

05/14/2026, 5:00 PM • GlobeNewswire

Management team’s 2025 market-based Options have vested

Precipio, Inc. (NASDAQ: PRPO) announced that 2025 employee stock options for management vested after the company's stock price increased 400% to a 10-day VWAP of $30.30 from the grant price of $6.06. The company replaced traditional time-based vesting with market-based vesting to align management incentives with shareholder interests. A similar structure was implemented for 2026 options with a target price of $40, resulting in an $800,000 non-cash stock compensation expense in Q1 2026.

05/13/2026, 5:00 PM • GlobeNewswire

Precipio Announces Q1-2026 Shareholder Update Call

Precipio, Inc. (NASDAQ: PRPO), a specialty cancer diagnostics company, announced it will host its Q1-2026 shareholder update call on May 18th, 2026, at 5:00 PM ET. The call will feature management remarks on core businesses and will mark the first time the company incorporates a dedicated moderated live Q&A session into its quarterly update call, demonstrating the company's commitment to shareholder transparency and engagement.

05/06/2026, 5:00 PM • GlobeNewswire

Precipio Announces Q4 and year-end 2025 Shareholder Update Call

Precipio, Inc. (NASDAQ: PRPO), a specialty cancer diagnostics company, announced a corporate update call scheduled for April 2, 2026, to discuss Q4 and year-end 2025 results. The company reported preliminary unaudited revenues of $24.0M for 2025, representing a 30% year-over-year increase. Additionally, Precipio published a joint study with Memorial Sloan-Kettering Cancer Center on its Bloodhound BCR::ABL1 assay in the Journal of Clinical Pathology.

03/12/2026, 5:00 PM • GlobeNewswire

Precipio Takes Major Steps Toward a Clean Balance Sheet

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced significant balance sheet improvements by repaying a $1.1 million advance from Change Healthcare and completing the exercise of all financial warrants issued in 2023. The company now maintains a nearly debt-free balance sheet with only an $80,000 Connecticut state loan remaining, positioning itself to focus on profitable operations and shareholder value creation.

01/15/2026, 9:00 AM • GlobeNewswire

Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting

Precipio conducted a comprehensive study with Memorial Sloan Kettering Cancer Center, evaluating their BCR::ABL1 assay using 895 patient samples. The study demonstrated superior performance and positive impacts on patient care and laboratory workflows.

12/05/2025, 10:00 AM • GlobeNewswire

Precipio Announces Q3-2025 Shareholder Update Call

Specialty cancer diagnostics company Precipio will host its Q3-2025 corporate update call on November 17th, 2025 at 5:00 PM ET, providing updates on its core businesses and diagnostic technologies.

11/04/2025, 5:00 PM • GlobeNewswire

Precipio Announces its Q2-2025 Financial Results

Precipio reported Q2-2025 revenues of $5.7M, a 27% year-over-year increase, with improvements in both Products and Pathology Services divisions. The company expects to end the year cash flow positive and debt-free, driven by revenue growth and cost management.

08/13/2025, 5:00 PM • GlobeNewswire

Precipio Enters Into Agreement With Warrant Holder To Exercise Majority Of Warrants As Cashless

Precipio has modified its warrant exercise structure, reducing potential share dilution and receiving approximately $1.2M in cash by changing the exercise method for 300,000 warrants.

07/11/2025, 4:30 PM • GlobeNewswire